Clinical Trial Update: Study Of Intrabucally Administered Electromagnetic Fields and Regorafenib [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating intrabuccally administered electromagnetic fields in combination with regorafenib for hepatocellular carcinoma was terminated, with r…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Regorafenib (Stivarga) (regorafenib)

Snippet

Sponsor: Wake Forest University Health Sciences | Conditions: Hepatocellular Carcinoma | Phase 2 | Status: TERMINATED | Results posted: 2026-03-05